Progress in adoptive cell therapy enables immune cells to be armed with robust multi-weapons that recognize and kill cancer cells expressing mutant KRAS–specific neoantigens, thereby overcoming immune evasion, low efficacy, and specificity hurdles. The gene discussed is KRAS; the disease is cancer.